New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - carvedilol 6.25mg;   - tablet - 6.25 mg - active: carvedilol 6.25mg   excipient: colloidal silicon dioxide crospovidone iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose povidone - carvedilol sandoz is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate 100 mg - fluvoxamine maleate extended-release capsules are indicated for the treatment of obsessive compulsive disorder (ocd), as defined in the dsm-iv. obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. the efficacy of fluvoxamine maleate extended-release capsules was demonstrated in one 12-week trial in adults with fluvoxamine maleate extended-release capsules as well as in two 10-week trials in adults and in one 10-week trial in children and adolescents (ages 8 to 17 years) with immediate-release fluvoxamine tablets in outpatients with the diagnosis of ocd as defined in dsm-iv or dsm-iii-r (see clinical studies [14.1, 14.3]) . the efficacy of fluvoxa

United States - English - NLM (National Library of Medicine)

jazz pharmaceuticals, inc. - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate 100 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carvedilol, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow; iron oxide red - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide red; iron oxide yellow - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 3.125 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide red - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).